U.S. Banks Stock News

NYSE:KGS
NYSE:KGSEnergy Services

Why Kodiak Gas Services (KGS) Is Up 7.8% After Record 2025 Results And Power Push

Kodiak Gas Services recently reported fourth-quarter 2025 revenue of US$332.87 million and net income of US$24.63 million, capping a record full year with US$1.31 billion in revenue and US$80.52 million in net income. The company paired this strong performance with a US$6.34 million long-lived asset impairment and the announcement of an expansion into power generation through acquiring Distributed Power Solutions, supported by technology-driven efficiency gains and higher dividends. We’ll...
NYSE:ROG
NYSE:ROGElectronic

How Investors Are Reacting To Rogers (ROG) Net Loss, Softer Sales And Completed Buyback Program

In February 2026, Rogers Corporation reported full-year 2025 results showing sales of US$810.8 million versus US$830.1 million a year earlier and a net loss of US$61.8 million, alongside first-quarter 2026 sales guidance of US$193 million to US$208 million. The company also disclosed that it has completed a long-running buyback program, repurchasing 2,120,103 shares, or 11.48% of its share count, for US$147.44 million since 2015, which may influence how investors weigh recent losses against...
NYSE:SILA
NYSE:SILAHealth Care REITs

How Investors Are Reacting To Sila Realty Trust (SILA) Softer Earnings And Steady US$0.40 Dividend

Sila Realty Trust, Inc. reported past fourth-quarter and full-year 2025 results showing higher revenue of US$50.7 million for the quarter and US$197.54 million for the year, but lower net income of US$5.02 million and US$33.12 million respectively, while funds from operations reached US$30.4 million in Q4 and US$120.9 million for 2025. Alongside these earnings, the board approved a US$0.40 per-share quarterly dividend and highlighted high occupancy, strong lease retention, and active...
NYSE:TR
NYSE:TRFood

Did Stronger 2025 Results and a Steady Dividend Just Shift Tootsie Roll Industries' (TR) Investment Narrative?

Tootsie Roll Industries, Inc. has reported its full-year 2025 results, with sales of US$7.85 million, revenue of US$732.52 million, and net income of US$100.05 million, while also affirming a quarterly dividend of US$0.09 per share payable on March 27, 2026. The increase in both revenue and net income, alongside higher basic earnings per share from continuing operations, points to improved profitability and operating efficiency. We’ll explore how this earnings growth and dividend affirmation...
NYSE:CTEV
NYSE:CTEVHealthcare Services

Claritev (CTEV) Is Down 42.1% After Launching $75 Million Buyback Amid Ongoing Losses - What's Changed

Claritev Corporation recently reported past fourth-quarter 2025 sales of US$246.55 million and a net loss of US$80.57 million, alongside full-year 2025 sales of US$965.41 million and a net loss of US$284.28 million, and announced a new share repurchase program of up to US$75 million running through 2030. While the company remains loss-making, the year-on-year reduction in losses and the commitment to buying back shares suggest management is focused on improving financial discipline and...
NasdaqGS:PRDO
NasdaqGS:PRDOConsumer Services

Assessing Perdoceo Education’s (PRDO) Valuation After Earnings Growth Guidance And Dividend Affirmation

Perdoceo Education (PRDO) drew fresh attention after reporting fourth quarter and full year 2025 earnings, issuing new 2026 guidance, and affirming its quarterly dividend, giving investors several data points to reassess the stock. See our latest analysis for Perdoceo Education. The recent earnings, 2026 guidance and dividend affirmation come after a period of steady share price strength, with a 90 day share price return of 19.83% and a 1 year total shareholder return of 32.10% supporting a...
NasdaqGM:WLDN
NasdaqGM:WLDNProfessional Services

A Look At Willdan Group (WLDN) Valuation After Record Results And New US$49 Million Energy Contract

Willdan Group (WLDN) is back in focus after reporting higher fourth quarter and full year revenue and net income, alongside a new US$49 million energy services contract with Mt. San Antonio College in California. See our latest analysis for Willdan Group. Despite the strong contract wins and record financial results, Willdan Group’s share price has seen a sharp pullback recently, with a 1 day share price return of negative 25.47% and a 30 day share price return of negative 29.37%. At the same...
NYSE:UCB
NYSE:UCBBanks

Assessing Whether United Community Banks (UCB) Still Looks Undervalued After Recent Share Price Weakness

Without a specific news announcement driving attention today, United Community Banks (UCB) still offers investors concrete data points to consider, including recent share performance, profitability metrics, and value-focused scores. See our latest analysis for United Community Banks. At a share price of $32.17, United Community Banks has seen a 6.56% 1 month share price decline, while its 90 day share price return of 3.91% and 1 year total shareholder return of 3.10% point to relatively...
NYSE:PIPR
NYSE:PIPRCapital Markets

Is Piper Sandler (PIPR) Quietly Recasting Its Healthcare Brand Around High-Margin Advisory Niches?

Piper Sandler Companies recently expanded its healthcare investment banking franchise, appointing Jason Arnold as a managing director focused on life science tools and diagnostics and naming Aamer Naseer global head of life sciences outsourcing and B2B med tech. These hires deepen Piper Sandler’s sector expertise at a time when life sciences outsourcing and diagnostics are increasingly central to healthcare deal and capital-raising activity. We’ll now examine how this refreshed life sciences...
NYSE:GKOS
NYSE:GKOSMedical Equipment

Glaukos (GKOS) Valuation Check As iDose Sales Momentum Meets Impairment Charge And Upbeat 2026 Outlook

Glaukos (GKOS) is back in focus after its fourth quarter 2025 report paired strong sales figures with a sizeable impairment charge, followed shortly by fresh 2026 sales guidance and a new ESOP related shelf registration. See our latest analysis for Glaukos. The recent impairment charge and ESOP related shelf registration come against a backdrop of steady share price gains, with a 90 day share price return of 13.28% and a very large 3 year total shareholder return of 139.03%. This suggests...
NasdaqGM:ALNT
NasdaqGM:ALNTElectrical

Assessing Allient (ALNT) Valuation As Operational Headwinds And Capital Choices Pressure Growth

Allient’s recent challenges come into focus Recent commentary on Allient (ALNT) has focused on two years of annual sales and earnings declines, alongside new share issuances and weaker returns on capital, raising fresh questions about how efficiently the business is being run. See our latest analysis for Allient. Allient’s recent share price has eased back, with a 1-day share price return of a 1.9% decline and a 7-day share price return of a 3.7% decline. However, the 90-day share price...
NasdaqGS:XERS
NasdaqGS:XERSPharmaceuticals

Xeris Biopharma Holdings (XERS) Is Down 7.4% After Suing to Block Recorlev Generics Until 2040

Xeris Biopharma recently filed a Hatch-Waxman patent infringement lawsuit in the US District Court for the District of New Jersey against Torrent Pharmaceuticals and Somerset Therapeutics, seeking to block generic versions of its Cushing’s syndrome therapy Recorlev until its patents expire in March 2040. This legal move highlights how central Recorlev’s intellectual property protection is to Xeris’s long-term product exclusivity and potential revenue longevity in its endocrine...
NYSE:SEE
NYSE:SEEPackaging

Assessing Sealed Air (SEE) Valuation As Shares Trade Near Recent Levels

Why Sealed Air is on investors’ radar today Sealed Air (SEE) is back in focus after recent trading left the shares around $41.88, prompting investors to reassess how its packaging business and current valuation line up with their expectations. See our latest analysis for Sealed Air. While the 1-day and 7-day share price returns are slightly negative, Sealed Air’s 1-year total shareholder return of 25.46% contrasts with weaker 3-year and modest 5-year total shareholder returns, which suggests...
NYSE:GEF
NYSE:GEFPackaging

Assessing Greif (GEF) Valuation As Mixed Near‑Term Returns Contrast With Longer‑Term Gains

Greif stock moves and recent performance snapshot Greif (GEF) has attracted fresh attention after a period of mixed short term returns, including a 0.1% one day slip and a 2.6% decline over the past week, alongside positive longer term performance. With the shares last closing at US$72.67 and total return figures of 3% over the past month and 9.4% over the past 3 months, investors are reassessing how this industrial packaging company fits into their portfolios. See our latest analysis for...
NYSE:RLI
NYSE:RLIInsurance

Will A++ Upgrade and New Debt Deal Change RLI's (RLI) Risk‑Reward Narrative for Investors?

In late February 2026, RLI Corp. completed a US$300 million fixed-rate senior unsecured bond offering of 5.375% Notes due June 1, 2036, following a new debt shelf registration and alongside a board decision to maintain its quarterly dividend at US$0.16 per share, extending a 50-year dividend increase streak. A recent AM Best upgrade of RLI Group’s financial strength rating to A++, coupled with an equity-backed partnership with AI-focused insurer Kettle to launch a new multi-peril commercial...
NasdaqGM:EYPT
NasdaqGM:EYPTPharmaceuticals

Is EyePoint (EYPT) Recasting Its Ophthalmology Playbook With a Veteran Launch Executive at DURAVYU?

EyePoint, Inc. recently appointed Michael Campbell as Chief Commercial Officer, giving him responsibility for commercial strategy and launch preparation for DURAVYU, its Phase 3 retinal disease candidate. The hire brings in a leader who helped shape the commercial playbooks behind Lucentis, Xiidra, Beovu and Tyrvaya, directly relevant to DURAVYU’s target markets. We’ll now examine how adding a veteran ophthalmology launch executive to oversee DURAVYU’s commercialization may influence...
NYSE:XYL
NYSE:XYLMachinery

Will Xylem’s (XYL) New $1.5 Billion Buyback and Dividend Hike Change Its Capital Allocation Narrative?

On February 25, 2026, Xylem Inc. (NYSE: XYL) authorized a new US$1.50 billion share repurchase program with no expiration date, alongside an 8% increase in its quarterly dividend. The combination of a sizable buyback, higher dividend, and recent record profitability underlines management’s confidence in Xylem’s cash generation and balance sheet strength. We’ll now examine how Xylem’s sizeable new buyback authorization could reshape its investment narrative around capital allocation and...
NasdaqGS:BMRN
NasdaqGS:BMRNBiotechs

A Look At BioMarin (BMRN) Valuation After Recent Share Price Rebound And Undervaluation Debate

Event driven snapshot of BioMarin Pharmaceutical BioMarin Pharmaceutical (BMRN) is back on investor radars after recent share price moves, with the stock up about 8% over the past month and roughly 10% over the past 3 months. See our latest analysis for BioMarin Pharmaceutical. While the recent 30 day share price return of about 8% and 90 day gain of roughly 10% suggest momentum is building again, the 1 year total shareholder return of about a 13% decline and a roughly 39% decline over three...
NYSE:EMR
NYSE:EMRElectrical

Emerson Electric (EMR) Valuation Check After Q1 2026 Beat And Raised EPS Outlook

Emerson Electric (EMR) is back on investors’ radar after its Q1 2026 earnings report and a higher full year EPS forecast, with management pointing to electrification and nearshoring as key demand drivers. See our latest analysis for Emerson Electric. The Q1 earnings beat and raised EPS guidance arrived after a strong run, with a 90 day share price return of 14.26% and a 1 year total shareholder return of 26.02%, suggesting momentum has been building over both shorter and longer periods. If...
NYSE:DTM
NYSE:DTMOil and Gas

A Look At DT Midstream (DTM) Valuation After Strong 2025 Results And Higher Dividend

DT Midstream (DTM) is back in focus after reporting full year 2025 results, with sales of US$1,243 million and net income of US$441 million. The company also announced a 7% quarterly dividend increase to US$0.88 per share. See our latest analysis for DT Midstream. DT Midstream’s recent earnings and dividend update come after a strong run in the shares, with the latest share price at US$138.84 and a 30 day share price return of 10.66%. The 1 year total shareholder return sits at 49.01% and the...
NYSE:BOBS
NYSE:BOBSSpecialty Retail

A Look At Bob’s Discount Furniture (BOBS) Valuation After Recent Share Price Momentum Cools

Why Bob's Discount Furniture stock is drawing attention now Bob's Discount Furniture (BOBS) is on some investors' radar after its recent share price moves, with the stock flat over the past day but lower over the past week. At a last close of US$21.24, the retailer of home furnishings, mattresses, and accessories is showing a year to date return of about 24.8%, which has prompted closer scrutiny of its current valuation. See our latest analysis for Bob's Discount Furniture. The recent 7 day...
NasdaqGM:SEPN
NasdaqGM:SEPNPharmaceuticals

Why Septerna (SEPN) Is Up 6.4% After Surging GPCR Pipeline-Driven Revenue Growth - And What's Next

Septerna, Inc. recently reported very large revenue growth, underpinned by progress in its GPCR-based oral small molecule pipeline for diseases including hypoparathyroidism, chronic spontaneous urticaria, and Graves’ disease. This surge in activity has coincided with strong analyst enthusiasm for Septerna’s advancing clinical programs, underscoring how pipeline momentum is reshaping its business profile within biotechnology. Next, we’ll examine how this very large revenue growth and...
NYSE:RERE
NYSE:RERESpecialty Retail

A Look At ATRenew (NYSE:RERE) Valuation After Strong Growth And Rising Investor Optimism

ATRenew (RERE) is back in focus after recent coverage highlighted revenue growth of 22% and earnings expanding more than fourfold, as investors look ahead to its March 11, 2026 unaudited 2025 results release. See our latest analysis for ATRenew. That backdrop helps explain why investor sentiment has shifted, with a 90 day share price return of 26.42% and a 1 year total shareholder return of 104.59%. This comes even though the latest 1 day move was a 3.34% share price decline to US$5.79,...
NasdaqGS:VSEC
NasdaqGS:VSECAerospace & Defense

Assessing VSE (VSEC) Valuation After Earnings Beat And Record Aviation Revenue

VSE (VSEC) has just reported quarterly results that came in ahead of analyst expectations, with higher operating margins, record aviation revenue, and a 2026 growth outlook that factors in recent acquisitions. See our latest analysis for VSE. Those results come after a strong run in the shares, with the latest price at $227.07, a 90 day share price return of 30.31% and a 1 year total shareholder return of 92.15%. This points to strengthening momentum as investors reassess growth prospects and...